Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Rating) will be releasing its earnings data before the market opens on Monday, May 9th. Analysts expect Madrigal Pharmaceuticals to post earnings of ($3.75) per share for the quarter. Investors that wish to register for the company’s conference call can do so using this link.
Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Rating) last issued its quarterly earnings data on Thursday, February 24th. The biopharmaceutical company reported ($3.78) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($3.92) by $0.14. On average, analysts expect Madrigal Pharmaceuticals to post $-15 EPS for the current fiscal year and $-12 EPS for the next fiscal year.
NASDAQ MDGL opened at $70.00 on Monday. The company has a 50-day moving average price of $89.65 and a two-hundred day moving average price of $83.35. Madrigal Pharmaceuticals has a 52 week low of $52.33 and a 52 week high of $142.62.
Several equities analysts have recently issued reports on the company. Zacks Investment Research downgraded Madrigal Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday. JMP Securities reiterated a “buy” rating and set a $220.00 price target on shares of Madrigal Pharmaceuticals in a research report on Monday, February 7th. Finally, StockNews.com began coverage on Madrigal Pharmaceuticals in a report on Thursday, March 31st. They set a “sell” rating on the stock. Two equities research analysts have rated the stock with a sell rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $163.43.
Madrigal Pharmaceuticals Company Profile (Get Rating)
Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-Ã agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis.
- Get a free copy of the StockNews.com research report on Madrigal Pharmaceuticals (MDGL)
- Is The FOMC About To Spark A Massive Stock Market Correction?
- Enphase Energy Has a Sunny Future With Some Clouds in the Short Term
- Knight-Swift Transportation Stock is a Logistics Winner
- Why is Chevron Stock Falling After Strong Earnings?
- MarketBeat: Week in Review 4/25 – 4/29
Receive News & Ratings for Madrigal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.